Diagnostics growth drives Zoetis' latest acquisitionFebruary 14, 2020Four months after venturing into the world of reference laboratory services, Zoetis has bolstered its presence within the space through the acquisition of Ethos Diagnostic Science.
SPONSORED CONTENTThe Case for Year-Round Heartworm Prevention and Affordable OptionsVeterinarians are often more than just clinicians - they’re advisors, educators, and, increasingly, financial counselors. In today’s economy, pet owners may hesitate to invest in year-round prevention due to budget constraints; but, skipping even a few months of heartworm protection can have serious consequences. + Learn More
TGen, Ethos develop diagnosis test for canine lymphomaMay 24, 2019A new test may assist veterinarians in more accurately diagnosing canine lymphoma. Developed by Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), the test is based on the results of a study that analyzed 180 dogs with cancer. The teams used their test, ePARR, to confirm first whether the dogs in the study had lymphoma and then determined what type they had. Results indicate the test was more than 90 percent accurate among a range of lymphoma sample types. "An ongoing need exists for robust validation of molecular diagnostics in veterinary medicine. This study is an example of exhaustive validation of one such molecular test," says Will Hendricks, PhD, assistant professor in TGen's Integrated Cancer Genomics Division and one of the study's senior coauthors. "Overall, ePARR is more than 90 percent accurate across sample types and diagnostic settings." The researchers say not only could molecular-level investigations into dog DNA improve the health of dogs with cancer, but it could help understand cancer in humans, too.
ACVIM, VetBloom partner to build elearning platformJune 13, 2018The American College of Veterinary Internal Medicine (ACVIM) is partnering with VetBloom, the digital learning ecosystem from Ethos Veterinary Health, to create a virtual learning environment for ACVIM and its members. Also, VetBloom will develop an integrated online portal for tracking and reporting of data related to the Maintenance of Credential (MOC) program for ACVIM Diplomates, as well as for tracking of resident specialty training and credentials. Key aspects of the partnership include: A fully branded ACVIM learning site with custom resources for members Paperless, online, automated MOC and resident specialty tracking An ACVIM eCommerce portal for nonmembers Ongoing digital access to ACVIM events Access to curated education from VetBloom and other members of the VetBloom learning community "Both ACVIM and VetBloom bring rich and complementary knowledge and experience to the relationship, and this presents us with a synergistic opportunity to develop a learning ecosystem that creates tremendous benefit for a number of audiences," said Patrick Welch, DVM, MBA, DACVO, chief knowledge officer of Ethos Veterinary Health. "VetBloom is a trusted resource in the veterinary field," said Veronica Muñoz, ACVIM CEO. "We look forward to combining VetBloom's expertise in developing veterinary education …
LexaGene, Ethos Veterinary Health partner for pathogen detection testingApril 6, 2018LexaGene has partnered with Ethos Veterinary Health, which has hospitals across the U.S., to test canine urine samples on LexaGene's prototype LX6 diagnostic tool for more effective, rapid and on-site pathogen detection. The samples have been previously characterized using conventional technologies such as MALDI-TOF mass spectrometry at LexaGene's reference laboratory, the company said. The organization is currently developing the LX6 tool as an open access, fully automated platform that allows end users to load real-time PCR assays. It will process six samples at a time and return results in around an hour, according to the company. "Veterinarians at Ethos will send LexaGene clinical annotated samples for processing, which will allow our team to continue to fine-tune and perfect our pathogen detection prototype's testing capabilities," said Jack Regan, Ph.D., LexaGene CEO. "This process is vital as we improve sensitivity to different isolates. We expect this to be a long-lasting collaboration as we work together to bring the best product possible to the veterinary market." "We've recently performed a market assessment for LexaGene's technology by interviewing many emergency and critical care veterinarians, and—coupled with an internal financial assessment of the cost of conventional testing versus …
